No One Dies Of Breast Cancer –Patients Die Because Breast Cancer Spreads To Their lungs

Barrons Medical Journal Reporting From Duke University Medical School Durham, NC

---

---

No One Dies Of Breast Cancer –Patients Die Because Breast Cancer Spreads To Their lungs

---

Durham, NC ( AP ) Now that the Fiscal Cliff is all finish it is now time to focus our attention to stopping Breast Cancer in its Tracks. To find a cure we must first

stop folks from dying from breast cancer. The spread of breast cancer is responsible for more than 90 percent of breast cancer deaths. The process by which breast cancer spreads -- or metastasizes is where Barrons Medical Journal is going to focus. Metastasis was long thought as a late event in breast cancer progression, With Genomics we now shown metastasis to be an early event that is dependent on HIF-1. HIF-1 protein controls genes that enable cells to survive in low oxygen, like cells in solid breast tumors.

In order for breast cancer cells to spread to lungs, they must leave the breast,

enter blood vessels that lead to the lungs, and exit those same vessels. "Blood vessels are pretty tight; a cell has to work pretty hard to get through the vessel wall. How this process works is breast cancer cells turn on genes called ANGPTL4, ANGPTL4, helps breast cancer to travel through blood vessel walls.

Research is now being performed with Genomics. The Gennxeix Biotech Team found by injecting these cells either with normal or "knocked-down" levels of ANGPTL4 into mice and examining their lungs. Cells lacking HIF-1 and containing extra ANGPTL4 were better able to invade the lungs than cells without extra ANGPTL4.

Barron Medical Journal Interviewed Gennxeix Biotech Chief Science Officer. Gennxeix Biotech found involvement in human breast cancer progression, based on the analysis of human breast cancer biopsies and experimental animal mice models. HIF-1 as a therapeutic target can extend the life of many stage four breast Cancer patients.
Gennxeix discovered The tumor suppressors VHL (von Hippel-Lindau protein) and p53 target HIF-1α for ubiquitination to inactivation breast cancer tumors cells

increases the of HIF-1. This process Increased phosphatidylinositol 3-kinase (PI3K) and AKT. In breast cancer, increased activity of the HER2 (also known as neu) receptor tyrosine kinase is associated with increased tumor grade, chemotherapy resistance, and decreased patient survival. HER2 has also been implicated as an inducer of

VEGF expression. GenNXeix demonstrate that HER2 signaling induced by overexpression in mouse 3T3 cells or human MCF-7 breast cancer cells results in increased HIF-1α protein and VEGF mRNA expression that is dependent upon activity of PI3K, AKT (also known as protein kinase B), and the downstream kinase FRAP (FKBP-rapamycin-associated protein)
Gennxeix concern with patients with diabetes and breast cancer may not receive full Benefit of HIF-1. All women having access to a physician can have access to HIF-1 treatments